Omnicell (OMCL) 10-Q 4 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 27, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		37,453,725
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 26,936	$ 54,488
Accounts receivable, net of allowances of $5,019 and $4,796, respectively	151,010	150,303
Inventories	81,523	69,297
Prepaid expenses	26,001	28,646
Other current assets	10,511	12,674
Total current assets	295,981	315,408
Property and equipment, net	40,713	42,011
Long-term investment in sales-type leases, net	17,424	20,585
Goodwill	332,996	327,724
Intangible assets, net	180,206	190,283
Long-term deferred tax assets	5,627	4,041
Other long-term assets	36,954	35,051
Total assets	909,901	935,103
Current liabilities:
Accounts payable	53,287	27,069
Accrued compensation	31,251	26,722
Accrued liabilities	30,894	31,195
Long-term debt, current portion, net	10,910	8,410
Deferred revenue, net	85,370	87,516
Total current liabilities	211,712	180,912
Long-term deferred revenue	16,332	17,051
Long-term deferred tax liabilities	38,950	51,592
Other long-term liabilities	9,879	8,210
Long-term debt, net	183,526	245,731
Total liabilities	460,399	503,496
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 46,591 and 45,778 shares issued; 37,446 and 36,633 shares outstanding, respectively	46	46
Treasury stock at cost, 9,145 shares outstanding	(185,074)	(185,074)
Additional paid-in capital	549,958	525,758
Retained earnings	92,063	100,396
Accumulated other comprehensive loss	(7,491)	(9,519)
Total stockholders’ equity	449,502	431,607
Total liabilities and stockholders’ equity	$ 909,901	$ 935,103

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowances	$ 5,019	$ 4,796
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares, authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, authorized (in shares)	100,000,000	100,000,000
Common Stock, shares, issued (in shares)	46,591,000	45,778,000
Common stock, shares, outstanding (in shares)	37,446,000	36,633,000
Treasury stock, shares (in shares)	9,145,000	9,145,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Product	$ 128,056	$ 130,674	$ 226,986	$ 258,569
Services and other revenues	52,829	42,233	104,453	85,342
Total revenues	180,885	172,907	331,439	343,911
Cost of revenues:
Cost of product revenues	81,738	76,306	145,326	148,224
Cost of services and other revenues	21,172	18,584	43,946	37,725
Total cost of revenues	102,910	94,890	189,272	185,949
Gross profit	77,975	78,017	142,167	157,962
Operating expenses:
Research and development	16,911	13,794	33,714	27,632
Selling, general and administrative	63,468	64,341	128,093	128,596
Total operating expenses	80,379	78,135	161,807	156,228
Income (loss) from operations	(2,404)	(118)	(19,640)	1,734
Interest and other income (expense), net	196	(1,881)	(2,260)	(4,052)
Loss before provision for income taxes	(2,208)	(1,999)	(21,900)	(2,318)
Benefit from income taxes	(3,045)	(840)	(11,983)	(781)
Net income (loss)	$ 837	$ (1,159)	$ (9,917)	$ (1,537)
Net income (loss) per share:
Net loss per share - basic and diluted (in dollars per share)	$ 0.02	$ (0.03)	$ (0.27)	$ (0.04)
Weighted-average shares outstanding:
Weighted-average shares outstanding — basic (in shares)	37,250	35,987	37,046	35,864
Weighted-average shares outstanding — diluted (in shares)	38,370	35,987	37,046	35,864

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ 837	$ (1,159)	$ (9,917)	$ (1,537)
Other comprehensive income (loss), net of reclassification adjustments:
Unrealized gains (losses) on interest rate swap contracts	(153)	0	29	0
Foreign currency translation adjustments	1,076	(4,467)	1,999	(4,794)
Other comprehensive income (loss)	923	(4,467)	2,028	(4,794)
Comprehensive income (loss)	$ 1,760	$ (5,626)	$ (7,889)	$ (6,331)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating Activities
Net loss	$ (9,917)	$ (1,537)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	25,942	29,197
Loss on disposal of fixed assets	79	1
Share-based compensation expense	11,056	9,386
Income tax benefits from employee stock plans	11	681
Deferred income taxes	(12,646)	(3,877)
Amortization of debt financing fees	795	795
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(770)	(7,775)
Inventories	(12,226)	(6,919)
Prepaid expenses	2,645	(4,852)
Other current assets	202	78
Investment in sales-type leases	5,482	(6,558)
Other long-term assets	(34)	1,019
Accounts payable	23,357	6,736
Accrued compensation	4,529	210
Accrued liabilities	2,165	(2,195)
Deferred revenue	(2,865)	4,895
Other long-term liabilities	1,119	(2,398)
Net cash provided by operating activities	38,924	16,887
Investing Activities
Purchases of intangible assets, intellectual property and patents	(160)	(1,185)
Software development for external use	(6,748)	(6,681)
Purchases of property and equipment	(6,493)	(5,938)
Business acquisitions, net of cash acquired	(4,446)	(271,458)
Net cash used in investing activities	(17,847)	(285,262)
Financing Activities
Proceeds from debt	10,000	247,051
Repayment of debt and revolving credit facility	(70,500)	(22,500)
Payment for contingent consideration	0	(3,000)
Proceeds from issuances under stock-based compensation plans	15,783	8,639
Employees' taxes paid related to restricted stock units	(2,638)	(1,563)
Net cash provided by (used in) financing activities	(47,355)	228,627
Effect of exchange rate changes on cash and cash equivalents	(1,274)	(1,440)
Net decrease in cash and cash equivalents	(27,552)	(41,188)
Cash and cash equivalents at beginning of period	54,488	82,217
Cash and cash equivalents at end of period	26,936	41,029
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	641	593
Effect of adoption of new accounting standard	$ 1,582	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication, supply control systems and medication adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Europe. "Omnicell", "our", "us", "we" or the "Company" collectively refer to Omnicell, Inc. and its subsidiaries. Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of June 30, 2017 and December 31, 2016 , the results of its operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2017 and June 30, 2016 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company's annual report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 28, 2017. The Company's results of operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2017 are not necessarily indicative of results that may be expected for the year ending December 31, 2017 , or for any future period. Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the 2017 presentation. These reclassifications include: (i) provision for excess and obsolete inventories, and (ii) provision for the allowance for doubtful accounts have been reclassified/combined with inventories and accounts receivable within net cash provided by operating activities in the Consolidated Statements of Cash Flows. These changes are not material and do not impact previously disclosed net cash provided by operating activities, net cash used in investing activities, and net cash used by financing activities. Additionally, see "Recently adopted authoritative guidance" for the effects of first quarter adoption of ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation, and accounting for income taxes. Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 13, Segment and Geographical Information, for additional information on segment reporting. Recently adopted authoritative guidance In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The provision of ASU No. 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted the standard effective January 1, 2017. The impact of adoption was the recording of excess tax benefits within income tax expense, rather than in Additional Paid in Capital of $0.8 million and $2.6 million for the three and six months ended June 30, 2017, respectively. Additionally, in the first quarter of 2017, the Company recognized the previously unrecognized excess tax benefits using the modified retrospective transition method, which resulted in a cumulative-effect adjustment of $1.6 million to retained earnings. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in today’s two-step impairment test under ASC 350, “Intangibles-Goodwill and Other.” Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The standard eliminates the current ASC 350 requirement to calculate a goodwill impairment charge using Step 2. ASU 2017-14 is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019. Early adoption is permitted for annual and interim goodwill impairment testing dates after January 1, 2017. The Company adopted ASU 2017-04 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Condensed Consolidated Financial Statements or related disclosures for the period presented. In January 2017, the FASB issued ASU 2017-01, Business Combinations , which clarifies the definition of a business and provides a screen to determine when a set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company adopted ASU 2017-01 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Condensed Consolidated Financial Statements or related disclosures for the period presented. Recently issued authoritative guidance In May 2014, the FASB issued ASU 2014-09-Revenue from Contracts with Customers, which outlines a single, comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, accordingly, it is possible more judgment and estimates may be required within the revenue recognition process than is required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has recently issued several amendments to ASU 2014-09, including clarification on accounting for licenses of intellectual property and identifying performance obligations. ASU 2014-09 will be effective for the Company beginning January 1, 2018. The two permitted transition methods under ASU 2014-09 are the full retrospective method, in which case ASU 2014-09 would be applied to each prior reporting period presented and the cumulative effect of applying ASU 2014-09 would be recognized at the earliest period shown, or the modified retrospective method, in which case the cumulative effect of applying ASU 2014-09 would be recognized at the date of initial application. While the Company currently expects to apply the full retrospective method, the Company is continuing to evaluate the availability of information and resources necessary and may decide the benefit of applying the full retrospective method is not significant enough to support the cost. Currently, the Company is in the process of reviewing its historical contracts to quantify the impact on its consolidated financial statements. The most significant impact of the standard relates to accounting for term software license revenue, contingent income, and commission expense. Specifically, under the standard the Company expects to recognize revenue on term software licenses upon installation of the license rather than ratably over the life of the term license. Additionally, the standard no longer requires deferral of contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price which will result in earlier recognition of revenue. Finally, the standard requires expense to be recognized for incremental costs incurred to obtain a contract, primarily commission expense, on a systematic basis that is consistent with the transfer to the customer of the product and services to which the cost relates. Rather than recognize commission expense at the time of recognizing the related product revenue, the new standard will require commission expense to be recognized consistent with the timing of product and service revenue, including an estimate of the period of service renewals for the transaction. The company is also in the process of assessing the appropriate changes to its business processes and upgrading its systems and controls to support recognition and disclosure under ASU 2014-09. The Company expects to complete its assessment process within the next two quarters of 2017. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company's Condensed Consolidated Financial Statements through the reporting date.

Business Acquisitions

Business Acquisitions	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions 2017 Acquisitions On April 12, 2017, the Company completed the acquisition of all of the membership interest of Dixie Drawl, LLC d/b/a InPharmics ("InPharmics") pursuant to InPharmics' Member Interest Purchase Agreement. InPharmics is a technology and services company that provides advanced pharmacy informatics solutions to hospital pharmacies. The total consideration for the transaction was $5.0 million , net of cash on hand at signing of $0.3 million . Approximately $0.5 million of the total consideration was classified as a long-term liability for potential settlement of performance obligations. The Company accounted for the acquisition of InPharmics in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The purchase price was preliminary allocated to intangible assets in the amount of $1.9 million , which included developed technology and customer contracts, with the remainder allocated to goodwill. The results of the InPharmics' operations have been included in our consolidated results of operations, and presented as part of the Automation and Analytics segment. 2016 Acquisitions On January 5, 2016, the Company completed the acquisition of all of the membership interests of Aesynt pursuant to the Aesynt Securities Purchase Agreement. Aesynt is a provider of automated medication management systems, including dispensing robots with storage solutions, medication storage and dispensing carts and cabinets, I.V. sterile preparation robotics, and software, including software related to medication management. The total consideration was $271.5 million , net of cash on hand at signing of $8.2 million . The results of Aesynt's operations have been included in the Company's consolidated results of operations as of the time of the acquisition, and presented as part of the Automation & Analytics segment. On December 8, 2016, the Company completed its acquisition of ateb, Inc., and Ateb Canada Ltd. (together, “Ateb”) pursuant to Ateb's Securities Purchase Agreement for $40.7 million of cash consideration, net of $0.9 million cash on hand. The cash consideration, included the repayment of Ateb indebtedness and other adjustments provided for in the Ateb's Securities Purchase Agreement. Ateb is a provider of pharmacy-based patient care solutions and the medication synchronization solutions leader to independent and chain pharmacies. The results of Ateb's operations have been included in the Company's consolidated results of operations as of the time of the acquisition, and presented as part of the Medication Adherence segment. The Company accounted for the acquisitions of Aesynt and Ateb in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition dates, respectively. The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb Total (in thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,842 51,154 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,208 84,492 Property and equipment 10,389 2,447 12,836 Intangibles 123,700 12,500 136,200 Goodwill 163,599 20,895 184,494 Other non-current assets 968 1,009 1,977 Total assets 372,940 47,059 419,999 Current liabilities 26,753 2,314 29,067 Deferred revenue 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 5,457 98,775 Total purchase price $ 279,622 $ 41,602 $ 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158 The $163.6 million of goodwill arising from the Aesynt acquisition is primarily attributed to sales of future products and services and Aesynt's assembled workforce. The goodwill has been assigned to the Automation & Analytics segment and is not deductible for tax purposes. The $20.9 million of goodwill arising from the Ateb acquisition is primarily attributed to sales of future products and services and Ateb's assembled workforce. Intangibles eligible for recognition separate from goodwill were those that satisfied either the contractual/legal criterion or the separability criterion in the accounting guidance. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — — In-process research and development (1) 3,900 — — — Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete. Aesynt Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Aesynt’s customers, acquired developed technology represents the fair value of Aesynt products that have reached technological feasibility and were part of Aesynt’s product offerings at the date of acquisition, backlog represents the fair value of sales order backlog at the date of acquisition, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Aesynt's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Aesynt’s products and services. In-process research and development ("IPR&D") represents the fair value of incomplete Aesynt research and development projects that had not reached technological feasibility as of the date of acquisition. Incremental costs incurred for those projects are expensed as incurred in research and development. The fair value of trade names, acquired developed technology, and acquired IPR&D was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% , 4% to 8% and 12.5% , respectively. The fair value of customer relationships, backlog, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, at the discounted rates of 13% , 10% and 13% , respectively. The intangible assets, except customer relationship and IPR&D, are being amortized over their estimated useful lives using the straight line method of amortization. The customer relationship intangible asset is being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. In accordance with authoritative guidance, the IPR&D is accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development efforts. IPR&D is tested for impairment during the period it is considered an indefinite lived asset. IPR&D related projects are expected to be completed in two to three years. As of June 30, 2017 , none of the IPR&D projects have been completed, and they have progressed as previously estimated. Ateb Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Ateb’s customers expected to result in future sales, acquired developed technology represents the fair value of Ateb intellectual property incorporated in their products, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Ateb's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Ateb’s products and services. The fair value of Ateb trade names and acquired developed technology was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% and 5% to 6% , respectively. The fair value of customer relationships, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, both using a 15% discount rate. The intangible assets for non-compete agreements and trade name are being amortized over their estimated useful lives using the straight line method of amortization. The intangible assets for customer relationship and developed technology are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period, less shares repurchased. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Any anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share. The basic and diluted net income (loss) per share calculation for the three and six months ended June 30, 2017 and 2016 is as follows: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 (In thousands, except per share data) Net income (loss) $ 837 $ (1,159 ) $ (9,917 ) $ (1,537 ) Weighted-average shares outstanding — basic 37,250 35,987 37,046 35,864 Effect of dilutive securities from stock award plans 1,120 — — — Weighted-average shares outstanding — diluted $ 38,370 $ 35,987 $ 37,046 35,864 Net income (loss) per share - basic $ 0.02 $ (0.03 ) $ (0.27 ) $ (0.04 ) Net income (loss) per share - diluted $ 0.02 $ (0.03 ) $ (0.27 ) $ (0.04 ) Anti-dilutive weighted-average shares related to stock award plans 2,121 1,961 4,039 2,037

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $26.9 million and $54.5 million as of June 30, 2017 and December 31, 2016 , respectively, consisted of demand deposits only. Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. In accordance with the 2015 Avantec share purchase agreement, the Company agreed to make potential earn-out payments of $3.0 million based on the achievement of bookings targets. The Company has concluded that as of June 30, 2017 only $2.4 million of the total potential earn out payment has been earned and will be paid out. The Company's contingent consideration liability is classified within Level 3, as original valuation inputs, which include the achievement of booking targets and the discount rate, were unobservable in the market and significant to the instrument's valuation. The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of June 30, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,274 $ — $ 1,274 Total financial assets $ — $ 1,274 $ — $ 1,274 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 There have been no transfers between fair value measurement levels during the six months ended June 30, 2017 and June 30, 2016 . The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 Net investment in sales-type leases. The carrying amount of the Company's sales-type lease receivables is a reasonable estimate of fair value, as the unearned interest income is immaterial. Interest Rate Swap Contracts The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company's interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes. During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counter-party that became effective on June 30, 2016 and is maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to a LIBOR floor of 0.0% . Amounts payable by or due to the Company will be net settled with the respective counter-party on the last business day of each month, commencing July 31, 2016. The fair value of the interest rate swap agreements at June 30, 2017 and December 31, 2016 was $1.3 million and $1.2 million , respectively. There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of June 30, 2017 and December 31, 2016 are presented in the tables below: June 30, December 31, (In thousands) Inventories: Raw materials $ 16,959 $ 14,322 Work in process 7,834 7,800 Finished goods 56,730 47,175 Total inventories $ 81,523 $ 69,297 Prepaid expense Prepaid commissions $ 10,658 $ 13,176 Other prepaid expenses 15,343 15,470 Total prepaid expense $ 26,001 $ 28,646 Property and equipment: Equipment $ 67,561 $ 64,384 Furniture and fixtures 6,666 6,517 Leasehold improvements 9,436 9,778 Software 36,712 35,607 Construction in progress 9,287 7,211 Property and equipment, gross 129,662 123,497 Accumulated depreciation and amortization (88,949 ) (81,486 ) Total property and equipment, net $ 40,713 $ 42,011 Other long term assets: Capitalized software, net $ 35,461 $ 33,233 Other assets 1,493 1,818 Total other long term assets, net $ 36,954 $ 35,051 June 30, December 31, Accrued liabilities: Advance payments from customers $ 8,588 $ 7,030 Rebates and lease buyouts 5,359 4,025 Group purchasing organization fees 3,068 3,737 Taxes payable 3,818 4,003 Other accrued liabilities 10,061 12,400 Total accrued liabilities $ 30,894 $ 31,195 The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the three and six months ended June 30, 2017 and 2016 : Three months ended June 30, 2017 2016 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (9,841 ) $ 1,427 $ (8,414 ) $ (3,057 ) $ — $ (3,057 ) Other comprehensive income (loss) before reclassifications 1,076 (100 ) 976 (4,467 ) — (4,467 ) Amounts reclassified from other comprehensive income (loss), net of tax — (53 ) (53 ) — — — Net current-period other comprehensive income (loss), net of tax 1,076 (153 ) 923 (4,467 ) — (4,467 ) Ending balance $ (8,765 ) $ 1,274 $ (7,491 ) $ (7,524 ) $ — $ (7,524 ) Six months ended June 30, 2017 2016 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (10,764 ) $ 1,245 $ (9,519 ) $ (2,730 ) $ — $ (2,730 ) Other comprehensive income (loss) before reclassifications 1,999 76 2,075 (4,794 ) — (4,794 ) Amounts reclassified from other comprehensive income (loss), net of tax — (47 ) (47 ) — — — Net current-period other comprehensive income (loss), net of tax 1,999 29 2,028 (4,794 ) — (4,794 ) Ending balance $ (8,765 ) $ 1,274 $ (7,491 ) $ (7,524 ) $ — $ (7,524 )

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	6 Months Ended
	Jun. 30, 2017
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases On a recurring basis, we enter into sales-type lease transactions which vary in length from one to five years. The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at June 30, 2017 and December 31, 2016 : June 30, December 31, (In thousands) Net minimum lease payments to be received $ 27,553 $ 33,591 Less: Unearned interest income portion (2,206 ) (2,763 ) Net investment in sales-type leases 25,347 30,828 Less: Short-term portion (1) (7,923 ) (10,243 ) Long-term net investment in sales-type leases $ 17,424 $ 20,585 (1) The short-term portion of the net investments in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The Company evaluates its sales-type leases individually and collectively for impairment. The allowance for credit losses were $0.2 million and $0.3 million as of June 30, 2017 and of December 31, 2016 , respectively. At June 30, 2017 , the future minimum lease payments under sales-type leases are as follows: June 30, (In thousands) Remaining six months of 2017 $ 4,967 2018 7,911 2019 5,915 2020 4,404 2021 2,647 Thereafter 1,709 Total $ 27,553

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2016 $ 215,082 $ 112,642 $ 327,724 Goodwill acquired 3,113 63 3,176 Foreign currency exchange rate fluctuations 1,592 504 2,096 Net balance as of June 30, 2017 $ 219,787 $ 113,209 $ 332,996 Goodwill acquired in the Automation and Analytics segment represents the value assigned to goodwill as part of the InPharmics acquisition. Goodwill acquired in the Medication Adherence segment represents adjustments to the preliminary value assigned to goodwill in connection with Ateb acquisition to reflect measurement period adjustments related to accounts receivable. Intangible assets, net The carrying amounts of intangibles assets as of June 30, 2017 and December 31, 2016 are as follows: June 30, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 132,744 $ (27,182 ) $ 459 $ 106,021 1 - 30 Acquired technology 74,188 (17,346 ) 158 57,000 3 - 20 Backlog 21,689 (15,689 ) — 6,000 1 - 5 Trade names 8,619 (4,272 ) 29 4,376 1 - 12 Patents 3,226 (1,283 ) 24 1,967 2 - 20 Non-compete agreements 1,900 (958 ) — 942 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 246,266 $ (66,730 ) $ 670 $ 180,206 December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283 Amortization expense of intangible assets was $6.8 million and $9.1 million for the three months ended June 30, 2017 and 2016 , respectively. Amortization expense of intangible assets was $13.0 million and $18.3 million for the six months ended June 30, 2017 and 2016 , respectively. The estimated future amortization expenses for amortizable intangible assets are as follows: June 30, 2017 (In thousands) Remaining six months of 2017 $ 12,514 2018 23,293 2019 17,828 2020 16,624 2021 15,053 Thereafter (excluding in-process technology) 90,994 Total $ 176,306

Debt

Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	Debt On January 5, 2016 , the Company entered into a $400 million senior secured credit facility pursuant to a credit agreement, by and among the Company, the lenders from time to time party thereto, Wells Fargo Securities, LLC, as Sole Lead Arranger and Wells Fargo Bank, National Association, as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (a) a five -year revolving credit facility of $200 million (the “Revolving Credit Facility”) and (b) a five -year $200 million term loan facility (the “Term Loan Facility” and together with the Revolving Credit Facility, the “Facilities”). In addition, the Credit Agreement includes a letter of credit sub-limit of up to $10 million and a swing line loan sub-limit of up to $10 million . The Credit Agreement expires on January 5, 2021, upon which date all remaining outstanding borrowings are due and payable. Loans under the Facilities bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% , and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the 2016 Credit Agreement). Undrawn commitments under the Revolving Credit Facility will be subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. A letter of credit participation fee ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio will accrue on the average daily amount of letter of credit exposure. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty, except for any amounts relating to the LIBOR breakage indemnity described in the Credit Agreement. The Company is required to make mandatory prepayments under the Term Loan Facility with (a) net cash proceeds from any issuances of debt (other than certain permitted debt) and (b) net cash proceeds from certain asset dispositions (other than certain asset dispositions) and insurance and condemnation events (subject to reinvestment rights and certain other exceptions). Loans under the Term Loan Facility will amortize in quarterly installments, equal to 5% per annum of the original principal amount thereof during the first two years, which shall increase to 10% per annum during the third and fourth years, and 15% per annum during the fifth year, with the remaining balance payable on January 5, 2021. The Company is required to make mandatory prepayments under the Revolving Credit Facility if at any time the aggregate outstanding principal amount of loans together with the total amount of outstanding letters of credit exceeds the aggregate commitments, with such mandatory prepayment to be equal to the amount of such excess. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total leverage ratio and maintain a minimum fixed charge coverage ratio. The Company’s obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and the subsidiary guarantors’ assets. In connection with entering into the Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a collateral agreement and subsidiary guaranty agreement. On January 5, 2016, the Company borrowed the full $200.0 million under the Term Loan Facility and $55.0 million under the Revolving Credit Facility to complete the Aesynt acquisition and pay related fees and expenses. On December 2, 2016, the Company borrowed $40.0 million under the Revolving Credit Facility to complete the Ateb acquisition and pay related fees and expenses. On April 3, 2017, the Company borrowed an additional $10.0 million under the Revolving Credit Facility to pay for the InPhamics acquisition and fund its operations. As of June 30, 2017 the Company has repaid $105.0 million borrowed under these Facilities, which includes $70.5 million repaid during the six months ended June 30, 2017 . On April 11, 2017, the parties entered into the First Amendment to Credit Agreement and Collateral Agreement. Under this amendment, (i) the maximum capital expenditures limit in any fiscal year for property, plant and equipment and software development increased from $35.0 million to $45.0 million , and (ii) the maximum limit for non-permitted investments increased from $10.0 million to $20.0 million . In connection with these Facilities, the Company incurred $7.9 million of debt issuance costs. The debt issuance costs were capitalized and presented as a direct deduction from the carrying amount of that debt liability in accordance with the accounting guidance. The debt issuance costs are being amortized to interest expense using the straight line method from issuance date through 2021. Interest expense (exclusive of fees and issuance cost amortization) was approximately $1.5 million and $1.2 million for the three months ended June 30, 2017 and 2016 , respectively. Interest expense (exclusive of fees and issuance cost amortization) was approximately $3.0 million and $2.8 million for the six months ended June 30, 2017 and 2016 , respectively. The Company was in full compliance with all covenants as of June 30, 2017 and December 31, 2016 . The components of the Company’s debt obligations for the six months ended June 30, 2017 are as follows: December 31, 2016 Borrowings Repayment / Amortization June 30, 2017 (In thousands) Term loan facility $ 192,500 $ — $ (5,000 ) $ 187,500 Revolving credit facility 68,000 10,000 (65,500 ) 12,500 Total debt under the facilities 260,500 10,000 (70,500 ) 200,000 Less: Deferred issuance cost (6,359 ) — 795 (5,564 ) Total Debt, net of deferred issuance cost $ 254,141 $ 10,000 $ (69,705 ) $ 194,436 Long term debt, current portion, net of deferred issuance cost 8,410 10,910 Long term debt, net of deferred issuance cost $ 245,731 $ 183,526 As of June 30, 2017 , the carrying amount of debt of $200.0 million approximates the comparable fair value of $200.9 million . The Company's debt facilities are classified as a Level 3 in the fair value hierarchy. The calculation of the fair value is based on a discounted cash flow model using observable market inputs and taking into consideration variables such as interest rate changes, comparable instruments, and long-term credit ratings.

Deferred revenue

Deferred revenue	6 Months Ended
	Jun. 30, 2017
Revenue Recognition [Abstract]
Deferred revenue	Deferred revenue Short-term deferred revenue includes deferred revenue from product sales and service contracts, net of deferred cost of sales of $13.9 million and $14.2 million as of June 30, 2017 and December 31, 2016 , respectively. The short-term deferred revenues from product sales relate to the delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. Long-term deferred revenue includes deferred revenue from service contracts of $16.3 million and $17.1 million , as of June 30, 2017 and December 31, 2016 , respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease commitments The Company leases office space and office equipment under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. At June 30, 2017 , the minimum future payments on non-cancelable operating leases were as follows: (In thousands) Remaining six months of 2017 $ 6,387 2018 12,411 2019 12,250 2020 10,979 2021 10,300 Thereafter 31,120 Total minimum future lease payments $ 83,447 Purchase obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. At June 30, 2017 , the Company had non-cancelable purchase commitments of $60.9 million , which are expected to be paid within the next twelve months. Legal Proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. The Company is not a party to any legal proceedings that management believes may have a material impact on the Company's financial position or results of operations.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company provides for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 41.1% and 38.3% for the six months ended June 30, 2017 and 2016 , respectively. The 2017 annual effective tax rate differed from the statutory rate of 35% primarily due to the unfavorable impact of state income taxes, foreign rate differential, and non-deductible equity charges, which were partially offset by the domestic production activities deduction and the Research & Development credits. The 2016 annual effective tax rate differed from the statutory rate of 35% primarily due to the favorable impact of the IRS settlement and release of tax reserves, the domestic production activities deduction, Research & Development credits and a calculated benefit in state income taxes, offset by unfavorable items such as non-deductible transaction costs related to the Aesynt transaction, and non-deductible equity charges under ASC 740-718. As of June 30, 2017 and December 31, 2016 , the Company had gross unrecognized tax benefits of $7.0 million and $6.5 million , respectively. It is the Company’s policy to classify accrued interest and penalties as part of the unrecognized tax benefits, but to record interest and penalties in operating expense. As of June 30, 2017 and December 31, 2016 , the amount of accrued interest and penalties was $1.1 million and $0.7 million , respectively. As of June 30, 2017 , calendar years 2011 and thereafter are open and subject to potential examination in one or more jurisdictions. However, our research credit carryforwards that may be used in future years are subject to adjustment, if and when utilized. As such our federal and California tax years remain open from 2015 and 1992, respectively. During fiscal 2016, the Internal Revenue Service and the Company settled all outstanding items related to the audit of the Company's federal income tax returns for the fiscal year ended December 31, 2014. Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock based plans For a detailed explanation of the Company's stock plans and subsequent changes, please refer to Note 11, Employee Benefits and Stock-Based Compensation, of the Company's Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 28, 2017. Share-based compensation expense The following table sets forth the total share-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three months ended Six months ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 (In thousands) Cost of product and service revenues $ 845 $ 644 $ 1,827 $ 1,193 Research and development 810 801 1,707 1,442 Selling, general and administrative 3,890 4,050 7,522 6,751 Total share-based compensation expense $ 5,545 $ 5,495 $ 11,056 $ 9,386 The following weighted average assumptions are used to value stock options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to the Company's equity incentive plans for the three and six months ended June 30, 2017 and 2016 : Three months ended Six months ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Stock Option Plans Expected life, years 4.67 4.92 4.67 4.92 Expected volatility, % 28.3 % 31.5 % 29.7 % 32.0 % Risk free interest rate, % 1.78 % 1.41 % 1.84 % 1.40 % Estimated forfeiture rate % 7.7 % 8.6 % 7.7 % 8.6 % Dividend yield, % — % — % — % — % Three months ended Six months ended June 30, June 30, June 30, 2017 June 30, 2016 Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 25.8-32.8% 25.8-34.8% 25.8-32.8% 25.8-34.8% Risk free interest rate, % 0.52-1.31% 0.26-0.79% 0.52-1.31% 0.26-0.79% Dividend yield, % — % — % — % — % Stock options activity The following table summarizes the share option activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Stock Options Outstanding at December 31, 2016 3,214 $ 26.06 7.3 $ 26,331 Granted 409 37.21 Exercised (423 ) 21.69 Expired (3 ) 24.36 Forfeited (56 ) 32.14 Outstanding at June 30, 2017 3,141 $ 27.99 7.4 $ 47,445 Exercisable at June 30, 2017 1,382 $ 21.61 5.6 $ 29,696 Vested and expected to vest at June 30, 2017 and thereafter 2,985 $ 27.66 7.3 $ 46,078 The weighted-average fair value per share of options granted during the three months ended June 30, 2017 and 2016 was $11.31 and $9.03 , respectively, and the weighted-average fair value per share of options granted during the six months ended June 30, 2017 and 2016 was $10.92 and $8.59 , respectively. The intrinsic value of options exercised during the three months ended June 30, 2017 and 2016 was $4.9 million and $2.2 million , respectively, and the intrinsic value of options exercised during the six months ended June 30, 2017 and 2016 was $7.8 million and $2.9 million , respectively, As of June 30, 2017 , total unrecognized compensation cost related to unvested stock options was $14.3 million , which is expected to be recognized over a weighted-average vesting period of 2.9 years. Restricted stock activity The following table summarizes the restricted stock activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units ("RSUs") Outstanding at December 31, 2016 505 $ 31.42 1.6 $ 17,135 Granted 86 37.21 Vested (96 ) 28.88 Forfeited (11 ) 32.17 Outstanding and unvested at June 30, 2017 484 $ 32.93 1.4 $ 20,901 The weighted-average grant date fair value per share of RSUs granted during the six months ended June 30, 2017 and June 30, 2016 was $37.21 and $28.09 , respectively. As of June 30, 2017 , total unrecognized compensation expense related to RSUs was $12.8 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.6 years. Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards ("RSAs") Outstanding at December 31, 2016 30 $ 31.57 Granted 24 41.10 Vested (30 ) 31.58 Forfeited — — Outstanding and unvested at June 30, 2017 24 $ 41.03 As of June 30, 2017 , total unrecognized compensation cost related to RSAs was $0.8 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.89 years . Performance-based restricted stock unit activity The following table summarizes the performance-based restricted stock activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units ("PSUs") Outstanding at December 31, 2016 184 $ 24.89 Granted 126 32.37 Vested (69 ) 24.43 Forfeited — — Outstanding and unvested at June 30, 2017 241 $ 28.94 The weighted-average grant date fair value per share of PSUs granted during the six months ended June 30, 2017 and 2016 was $32.37 and $24.66 , respectively. As of June 30, 2017 , total unrecognized compensation cost related to PSUs was $3.5 million , which is expected to be recognized over the remaining weighted-average period of 1.5 years. Employee Stock Purchase Plan activity For the six months ending June 30, 2017 and 2016 , purchases under the ESPP were approximately 259,000 and 198,000 shares at weighted average prices of $25.51 and $22.74 , respectively. As of June 30, 2017 , the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $1.9 million and is expected to be recognized over a weighted-average period of 1.3 years . Summary of shares reserved for future issuance under equity incentive plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of June 30, 2017 : Number of Shares (In thousands) Share options outstanding 3,141 Non-vested restricted share awards 749 Shares authorized for future issuance 2,310 ESPP shares available for future issuance 2,572 Total shares reserved for future issuance 8,772 Stock Repurchase Program On August 2, 2016, the Company's Board of Directors (the "Board") authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 (the “2014 Repurchase Program”). As of June 30, 2017 , the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million . The stock repurchase programs do not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase program at any time. During the three and six months period ended June 30, 2017 and 2016 , the Company did not repurchase any of its outstanding common stock.

Segment and Geographical Inform

Segment and Geographical Information	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment and Geographical Information	Segment and Geographical Information The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The two operating segments, which are the same as the Company's two reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Automation and Analytics products are designed to enable the Company's customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company's systems can be tailored to specific customer needs. Medication Adherence The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. These products are used to manage medication administration outside of the hospital setting and include medication adherence products, which consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities. The following tables summarize the financial performance of the Company's reportable segments, including a reconciliation of income from segment operations to income from total operations: Three months ended June 30, 2017 June 30, 2016 Automation and Medication Total Automation and Medication Total (In thousands) Revenues $ 148,427 $ 32,458 $ 180,885 $ 148,660 $ 24,247 $ 172,907 Cost of revenues 80,716 22,194 102,910 78,366 16,524 94,890 Gross profit 67,711 10,264 77,975 70,294 7,723 78,017 Operating expenses 49,054 10,099 59,153 49,780 5,771 55,551 Income (loss) from segment operations $ 18,657 $ 165 $ 18,822 $ 20,514 $ 1,952 $ 22,466 Corporate costs 21,226 22,584 Income (loss) from operations $ (2,404 ) $ (118 ) Six months ended June 30, 2017 June 30, 2016 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 272,598 $ 58,841 $ 331,439 $ 297,605 $ 46,306 $ 343,911 Cost of revenues 149,477 39,795 189,272 155,573 30,376 185,949 Gross profit 123,121 19,046 142,167 142,032 15,930 157,962 Operating expenses 99,801 21,295 121,096 101,985 11,382 113,367 Income (loss) from segment operations $ 23,320 $ (2,249 ) $ 21,071 $ 40,047 $ 4,548 $ 44,595 Corporate costs 40,711 42,861 Income (loss) from operations $ (19,640 ) $ 1,734 Significant customers There were no customers that accounted for more than 10% of our total revenues for the three and six months ended June 30, 2017 and 2016 . Also, there were no customers that accounted for more than 10% of our accounts receivable as of June 30, 2017 and December 31, 2016 . Geographical Information Revenues Three months ended June 30, June 30, (In thousands) United States $ 153,285 $ 145,988 Rest of world (1) 27,600 26,919 Total revenues $ 180,885 $ 172,907 Six months ended June 30, June 30, (In thousands) United States $ 285,565 $ 289,481 Rest of world (1) 45,874 54,430 Total revenues $ 331,439 $ 343,911 _________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net June 30, December 31, (In thousands) United States $ 35,041 $ 36,497 Rest of world (1) 5,672 5,514 Total property and equipment, net $ 40,713 $ 42,011 _________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net is attributed to the geographic location in which it is located.

Restructuring Expenses

Restructuring Expenses	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses On February 15, 2017, the Company announced its plan to reduce its workforce by approximately 100 full-time employees and close the Company’s Nashville, Tennessee and Slovenia facilities. The plan is expected to be completed in fiscal year 2017. The estimated total cost for the plan is $4.9 million , which includes estimated employee severance cost of approximately $3.8 million , and facility-related costs of approximately $1.1 million . During the six months ended June 30, 2017 , the Company accrued $ 3.8 million of severance and related expenses, and paid out $3.1 million . The remaining unpaid balance of $0.7 million accrued severance and related expenses as of June 30, 2017 is presented as a component of accrued compensation in the Condensed Consolidated Balance Sheet. There were $0.6 million of facility-related costs incurred during the six months ended June 30, 2017 , of which $0.1 million was paid out. The remaining unpaid balance of $0.5 million accrued facilities-related expenses as of June 30, 2017 is presented as a component of accrued liabilities in the Condensed Consolidated Balance Sheet. The following table summarizes the restructuring expense recorded in each reportable segment and income statement classification for the three months and six months ended June 30, 2017 . Three months ended Six months ended June 30, 2017 June 30, 2017 Automation and Analytics Medication Adherence Corporate Total Automation and Analytics Medication Adherence Corporate Total (in thousands) Cost of revenue $ — $ — $ — $ — $ 1,266 $ 431 $ — $ 1,697 Research and development 485 — 102 587 1,491 62 102 1,655 Selling, general and administrative — — 16 16 480 103 433 1,016 Restructuring and related expense $ 485 $ — $ 118 $ 603 $ 3,237 $ 596 $ 535 $ 4,368 During the second quarter of 2016, the Company integrated its Sales and Field organizations in North America to better serve its customers which resulted in a reduction in headcount of 36 employees. Accordingly, the Company incurred approximately $1.7 million of restructuring expenses in the second quarter ending June 30, 2016, based on agreements with terminated employees covering salary and benefit continuation. As of June 30, 2016 the restructuring program has been concluded.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On July 7, 2017 and July 31, 2017, the Company borrowed $15.0 million and $12.0 million , respectively, under the Revolving Credit Facility to fund its operations.

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of June 30, 2017 and December 31, 2016 , the results of its operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2017 and June 30, 2016 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company's annual report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 28, 2017. The Company's results of operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2017 are not necessarily indicative of results that may be expected for the year ending December 31, 2017 , or for any future period.
Principles of consolidation	Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Reclassification	Certain prior year amounts have been reclassified to conform to the 2017 presentation. These reclassifications include: (i) provision for excess and obsolete inventories, and (ii) provision for the allowance for doubtful accounts have been reclassified/combined with inventories and accounts receivable within net cash provided by operating activities in the Consolidated Statements of Cash Flows. These changes are not material and do not impact previously disclosed net cash provided by operating activities, net cash used in investing activities, and net cash used by financing activities.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation, and accounting for income taxes.
Segment reporting	Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 13, Segment and Geographical Information, for additional information on segment reporting.
Recently adopted and issued authoritative guidance	Recently adopted authoritative guidance In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The provision of ASU No. 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted the standard effective January 1, 2017. The impact of adoption was the recording of excess tax benefits within income tax expense, rather than in Additional Paid in Capital of $0.8 million and $2.6 million for the three and six months ended June 30, 2017, respectively. Additionally, in the first quarter of 2017, the Company recognized the previously unrecognized excess tax benefits using the modified retrospective transition method, which resulted in a cumulative-effect adjustment of $1.6 million to retained earnings. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in today’s two-step impairment test under ASC 350, “Intangibles-Goodwill and Other.” Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The standard eliminates the current ASC 350 requirement to calculate a goodwill impairment charge using Step 2. ASU 2017-14 is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019. Early adoption is permitted for annual and interim goodwill impairment testing dates after January 1, 2017. The Company adopted ASU 2017-04 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Condensed Consolidated Financial Statements or related disclosures for the period presented. In January 2017, the FASB issued ASU 2017-01, Business Combinations , which clarifies the definition of a business and provides a screen to determine when a set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company adopted ASU 2017-01 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Condensed Consolidated Financial Statements or related disclosures for the period presented. Recently issued authoritative guidance In May 2014, the FASB issued ASU 2014-09-Revenue from Contracts with Customers, which outlines a single, comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, accordingly, it is possible more judgment and estimates may be required within the revenue recognition process than is required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has recently issued several amendments to ASU 2014-09, including clarification on accounting for licenses of intellectual property and identifying performance obligations. ASU 2014-09 will be effective for the Company beginning January 1, 2018. The two permitted transition methods under ASU 2014-09 are the full retrospective method, in which case ASU 2014-09 would be applied to each prior reporting period presented and the cumulative effect of applying ASU 2014-09 would be recognized at the earliest period shown, or the modified retrospective method, in which case the cumulative effect of applying ASU 2014-09 would be recognized at the date of initial application. While the Company currently expects to apply the full retrospective method, the Company is continuing to evaluate the availability of information and resources necessary and may decide the benefit of applying the full retrospective method is not significant enough to support the cost. Currently, the Company is in the process of reviewing its historical contracts to quantify the impact on its consolidated financial statements. The most significant impact of the standard relates to accounting for term software license revenue, contingent income, and commission expense. Specifically, under the standard the Company expects to recognize revenue on term software licenses upon installation of the license rather than ratably over the life of the term license. Additionally, the standard no longer requires deferral of contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price which will result in earlier recognition of revenue. Finally, the standard requires expense to be recognized for incremental costs incurred to obtain a contract, primarily commission expense, on a systematic basis that is consistent with the transfer to the customer of the product and services to which the cost relates. Rather than recognize commission expense at the time of recognizing the related product revenue, the new standard will require commission expense to be recognized consistent with the timing of product and service revenue, including an estimate of the period of service renewals for the transaction. The company is also in the process of assessing the appropriate changes to its business processes and upgrading its systems and controls to support recognition and disclosure under ASU 2014-09. The Company expects to complete its assessment process within the next two quarters of 2017. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company's Condensed Consolidated Financial Statements through the reporting date.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed and Weighted Average Useful Life	The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb Total (in thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,842 51,154 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,208 84,492 Property and equipment 10,389 2,447 12,836 Intangibles 123,700 12,500 136,200 Goodwill 163,599 20,895 184,494 Other non-current assets 968 1,009 1,977 Total assets 372,940 47,059 419,999 Current liabilities 26,753 2,314 29,067 Deferred revenue 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 5,457 98,775 Total purchase price $ 279,622 $ 41,602 $ 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158
Intangible Assets Acquired as Part of Business Acquisition	The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — — In-process research and development (1) 3,900 — — — Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete.

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The basic and diluted net income (loss) per share calculation for the three and six months ended June 30, 2017 and 2016 is as follows: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 (In thousands, except per share data) Net income (loss) $ 837 $ (1,159 ) $ (9,917 ) $ (1,537 ) Weighted-average shares outstanding — basic 37,250 35,987 37,046 35,864 Effect of dilutive securities from stock award plans 1,120 — — — Weighted-average shares outstanding — diluted $ 38,370 $ 35,987 $ 37,046 35,864 Net income (loss) per share - basic $ 0.02 $ (0.03 ) $ (0.27 ) $ (0.04 ) Net income (loss) per share - diluted $ 0.02 $ (0.03 ) $ (0.27 ) $ (0.04 ) Anti-dilutive weighted-average shares related to stock award plans 2,121 1,961 4,039 2,037

Cash and Cash Equivalents and25

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured At Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of June 30, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,274 $ — $ 1,274 Total financial assets $ — $ 1,274 $ — $ 1,274 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 There have been no transfers between fair value measurement levels during the six months ended June 30, 2017 and June 30, 2016 . The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	Balance sheet details as of June 30, 2017 and December 31, 2016 are presented in the tables below: June 30, December 31, (In thousands) Inventories: Raw materials $ 16,959 $ 14,322 Work in process 7,834 7,800 Finished goods 56,730 47,175 Total inventories $ 81,523 $ 69,297 Prepaid expense Prepaid commissions $ 10,658 $ 13,176 Other prepaid expenses 15,343 15,470 Total prepaid expense $ 26,001 $ 28,646 Property and equipment: Equipment $ 67,561 $ 64,384 Furniture and fixtures 6,666 6,517 Leasehold improvements 9,436 9,778 Software 36,712 35,607 Construction in progress 9,287 7,211 Property and equipment, gross 129,662 123,497 Accumulated depreciation and amortization (88,949 ) (81,486 ) Total property and equipment, net $ 40,713 $ 42,011 Other long term assets: Capitalized software, net $ 35,461 $ 33,233 Other assets 1,493 1,818 Total other long term assets, net $ 36,954 $ 35,051 June 30, December 31, Accrued liabilities: Advance payments from customers $ 8,588 $ 7,030 Rebates and lease buyouts 5,359 4,025 Group purchasing organization fees 3,068 3,737 Taxes payable 3,818 4,003 Other accrued liabilities 10,061 12,400 Total accrued liabilities $ 30,894 $ 31,195
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the three and six months ended June 30, 2017 and 2016 : Three months ended June 30, 2017 2016 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (9,841 ) $ 1,427 $ (8,414 ) $ (3,057 ) $ — $ (3,057 ) Other comprehensive income (loss) before reclassifications 1,076 (100 ) 976 (4,467 ) — (4,467 ) Amounts reclassified from other comprehensive income (loss), net of tax — (53 ) (53 ) — — — Net current-period other comprehensive income (loss), net of tax 1,076 (153 ) 923 (4,467 ) — (4,467 ) Ending balance $ (8,765 ) $ 1,274 $ (7,491 ) $ (7,524 ) $ — $ (7,524 ) Six months ended June 30, 2017 2016 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (10,764 ) $ 1,245 $ (9,519 ) $ (2,730 ) $ — $ (2,730 ) Other comprehensive income (loss) before reclassifications 1,999 76 2,075 (4,794 ) — (4,794 ) Amounts reclassified from other comprehensive income (loss), net of tax — (47 ) (47 ) — — — Net current-period other comprehensive income (loss), net of tax 1,999 29 2,028 (4,794 ) — (4,794 ) Ending balance $ (8,765 ) $ 1,274 $ (7,491 ) $ (7,524 ) $ — $ (7,524 )

Net Investment in Sales-Type 27

Net Investment in Sales-Type Leases (Tables)	6 Months Ended
	Jun. 30, 2017
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at June 30, 2017 and December 31, 2016 : June 30, December 31, (In thousands) Net minimum lease payments to be received $ 27,553 $ 33,591 Less: Unearned interest income portion (2,206 ) (2,763 ) Net investment in sales-type leases 25,347 30,828 Less: Short-term portion (1) (7,923 ) (10,243 ) Long-term net investment in sales-type leases $ 17,424 $ 20,585 (1) The short-term portion of the net investments in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Schedule of Net Sale-Type Leases Minimum Lease Receivables	At June 30, 2017 , the future minimum lease payments under sales-type leases are as follows: June 30, (In thousands) Remaining six months of 2017 $ 4,967 2018 7,911 2019 5,915 2020 4,404 2021 2,647 Thereafter 1,709 Total $ 27,553

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2016 $ 215,082 $ 112,642 $ 327,724 Goodwill acquired 3,113 63 3,176 Foreign currency exchange rate fluctuations 1,592 504 2,096 Net balance as of June 30, 2017 $ 219,787 $ 113,209 $ 332,996
Intangible Assets, Net	The carrying amounts of intangibles assets as of June 30, 2017 and December 31, 2016 are as follows: June 30, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 132,744 $ (27,182 ) $ 459 $ 106,021 1 - 30 Acquired technology 74,188 (17,346 ) 158 57,000 3 - 20 Backlog 21,689 (15,689 ) — 6,000 1 - 5 Trade names 8,619 (4,272 ) 29 4,376 1 - 12 Patents 3,226 (1,283 ) 24 1,967 2 - 20 Non-compete agreements 1,900 (958 ) — 942 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 246,266 $ (66,730 ) $ 670 $ 180,206 December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets are as follows: June 30, 2017 (In thousands) Remaining six months of 2017 $ 12,514 2018 23,293 2019 17,828 2020 16,624 2021 15,053 Thereafter (excluding in-process technology) 90,994 Total $ 176,306

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt	The components of the Company’s debt obligations for the six months ended June 30, 2017 are as follows: December 31, 2016 Borrowings Repayment / Amortization June 30, 2017 (In thousands) Term loan facility $ 192,500 $ — $ (5,000 ) $ 187,500 Revolving credit facility 68,000 10,000 (65,500 ) 12,500 Total debt under the facilities 260,500 10,000 (70,500 ) 200,000 Less: Deferred issuance cost (6,359 ) — 795 (5,564 ) Total Debt, net of deferred issuance cost $ 254,141 $ 10,000 $ (69,705 ) $ 194,436 Long term debt, current portion, net of deferred issuance cost 8,410 10,910 Long term debt, net of deferred issuance cost $ 245,731 $ 183,526

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Payments on Non-Cancelable Operating Leases	At June 30, 2017 , the minimum future payments on non-cancelable operating leases were as follows: (In thousands) Remaining six months of 2017 $ 6,387 2018 12,411 2019 12,250 2020 10,979 2021 10,300 Thereafter 31,120 Total minimum future lease payments $ 83,447

Employee Benefits and Share-B31

Employee Benefits and Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three months ended Six months ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 (In thousands) Cost of product and service revenues $ 845 $ 644 $ 1,827 $ 1,193 Research and development 810 801 1,707 1,442 Selling, general and administrative 3,890 4,050 7,522 6,751 Total share-based compensation expense $ 5,545 $ 5,495 $ 11,056 $ 9,386
Estimate of Fair Value of Share-Based Awards, Share Options	The following weighted average assumptions are used to value stock options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to the Company's equity incentive plans for the three and six months ended June 30, 2017 and 2016 : Three months ended Six months ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Stock Option Plans Expected life, years 4.67 4.92 4.67 4.92 Expected volatility, % 28.3 % 31.5 % 29.7 % 32.0 % Risk free interest rate, % 1.78 % 1.41 % 1.84 % 1.40 % Estimated forfeiture rate % 7.7 % 8.6 % 7.7 % 8.6 % Dividend yield, % — % — % — % — %
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	Three months ended Six months ended June 30, June 30, June 30, 2017 June 30, 2016 Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 25.8-32.8% 25.8-34.8% 25.8-32.8% 25.8-34.8% Risk free interest rate, % 0.52-1.31% 0.26-0.79% 0.52-1.31% 0.26-0.79% Dividend yield, % — % — % — % — %
Stock Option Activity under the Equity Incentive Plans	The following table summarizes the share option activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Stock Options Outstanding at December 31, 2016 3,214 $ 26.06 7.3 $ 26,331 Granted 409 37.21 Exercised (423 ) 21.69 Expired (3 ) 24.36 Forfeited (56 ) 32.14 Outstanding at June 30, 2017 3,141 $ 27.99 7.4 $ 47,445 Exercisable at June 30, 2017 1,382 $ 21.61 5.6 $ 29,696 Vested and expected to vest at June 30, 2017 and thereafter 2,985 $ 27.66 7.3 $ 46,078
Restricted Stock Units Activity under the Stock Option Activity under the Equity Incentive Plans	The following table summarizes the restricted stock activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units ("RSUs") Outstanding at December 31, 2016 505 $ 31.42 1.6 $ 17,135 Granted 86 37.21 Vested (96 ) 28.88 Forfeited (11 ) 32.17 Outstanding and unvested at June 30, 2017 484 $ 32.93 1.4 $ 20,901
Restricted Stock Units Award under the Stock Option Activity under the Equity Incentive Plans	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards ("RSAs") Outstanding at December 31, 2016 30 $ 31.57 Granted 24 41.10 Vested (30 ) 31.58 Forfeited — — Outstanding and unvested at June 30, 2017 24 $ 41.03
Performance Shares Restricted Stock Activity under the Stock Option Activity under the Equity Incentive Plans	The following table summarizes the performance-based restricted stock activity under the Company’s equity incentive plans during the six months ended June 30, 2017 : Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units ("PSUs") Outstanding at December 31, 2016 184 $ 24.89 Granted 126 32.37 Vested (69 ) 24.43 Forfeited — — Outstanding and unvested at June 30, 2017 241 $ 28.94
Shares Reserved for Future Issuance under the Stock Option Activity under the Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of June 30, 2017 : Number of Shares (In thousands) Share options outstanding 3,141 Non-vested restricted share awards 749 Shares authorized for future issuance 2,310 ESPP shares available for future issuance 2,572 Total shares reserved for future issuance 8,772

Segment and Geographical Info32

Segment and Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following tables summarize the financial performance of the Company's reportable segments, including a reconciliation of income from segment operations to income from total operations: Three months ended June 30, 2017 June 30, 2016 Automation and Medication Total Automation and Medication Total (In thousands) Revenues $ 148,427 $ 32,458 $ 180,885 $ 148,660 $ 24,247 $ 172,907 Cost of revenues 80,716 22,194 102,910 78,366 16,524 94,890 Gross profit 67,711 10,264 77,975 70,294 7,723 78,017 Operating expenses 49,054 10,099 59,153 49,780 5,771 55,551 Income (loss) from segment operations $ 18,657 $ 165 $ 18,822 $ 20,514 $ 1,952 $ 22,466 Corporate costs 21,226 22,584 Income (loss) from operations $ (2,404 ) $ (118 ) Six months ended June 30, 2017 June 30, 2016 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 272,598 $ 58,841 $ 331,439 $ 297,605 $ 46,306 $ 343,911 Cost of revenues 149,477 39,795 189,272 155,573 30,376 185,949 Gross profit 123,121 19,046 142,167 142,032 15,930 157,962 Operating expenses 99,801 21,295 121,096 101,985 11,382 113,367 Income (loss) from segment operations $ 23,320 $ (2,249 ) $ 21,071 $ 40,047 $ 4,548 $ 44,595 Corporate costs 40,711 42,861 Income (loss) from operations $ (19,640 ) $ 1,734
Revenue by Geographical Location	Revenues Three months ended June 30, June 30, (In thousands) United States $ 153,285 $ 145,988 Rest of world (1) 27,600 26,919 Total revenues $ 180,885 $ 172,907 Six months ended June 30, June 30, (In thousands) United States $ 285,565 $ 289,481 Rest of world (1) 45,874 54,430 Total revenues $ 331,439 $ 343,911 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.
Long-lived Assets by Geographical Location	Property and equipment, net June 30, December 31, (In thousands) United States $ 35,041 $ 36,497 Rest of world (1) 5,672 5,514 Total property and equipment, net $ 40,713 $ 42,011 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring Expenses	The following table summarizes the restructuring expense recorded in each reportable segment and income statement classification for the three months and six months ended June 30, 2017 . Three months ended Six months ended June 30, 2017 June 30, 2017 Automation and Analytics Medication Adherence Corporate Total Automation and Analytics Medication Adherence Corporate Total (in thousands) Cost of revenue $ — $ — $ — $ — $ 1,266 $ 431 $ — $ 1,697 Research and development 485 — 102 587 1,491 62 102 1,655 Selling, general and administrative — — 16 16 480 103 433 1,016 Restructuring and related expense $ 485 $ — $ 118 $ 603 $ 3,237 $ 596 $ 535 $ 4,368 During the second quarter of 2016, the Company integrated its Sales and Field organizations in North America to better serve its customers which resulted in a reduction in headcount of 36 employees. Accordingly, the Company incurred approximately $1.7 million of restructuring expenses in the second quarter ending June 30, 2016, based on agreements with terminated employees covering salary and benefit continuation. As of June 30, 2016 the restructuring program has been concluded.

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies (Details) - ASU 2016-09 - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in accounting guidance, impact on net income	$ 0.8	$ 2.6
Retained Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of new accounting principle			$ 1.6

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Apr. 12, 2017	Dec. 08, 2016	Jan. 05, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Total purchase price, net of cash received				$ 4,446	$ 271,458
Goodwill				$ 332,996		$ 327,724
InPharmics LLC
Business Acquisition [Line Items]
Total purchase price, net of cash received	$ 5,000
Cash on hand at signing	300
Contingent consideration liability	500
Intangibles	$ 1,900
Aesynt Holding, L.P., Aesynt, Ltd.
Business Acquisition [Line Items]
Total purchase price, net of cash received			$ 271,458
Cash on hand at signing			8,164
Intangibles			123,700
Goodwill			$ 163,599
Aesynt Holding, L.P., Aesynt, Ltd. | Minimum
Business Acquisition [Line Items]
In process research and development, expected term (in years)				2 years
Aesynt Holding, L.P., Aesynt, Ltd. | Maximum
Business Acquisition [Line Items]
In process research and development, expected term (in years)				3 years
Aesynt Holding, L.P., Aesynt, Ltd. | In-process research and development (IPR&D)
Business Acquisition [Line Items]
Royalty rate				12.50%
Aesynt Holding, L.P., Aesynt, Ltd. | Trade names
Business Acquisition [Line Items]
Royalty rate				0.50%
Aesynt Holding, L.P., Aesynt, Ltd. | Developed technology | Minimum
Business Acquisition [Line Items]
Royalty rate				4.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Developed technology | Maximum
Business Acquisition [Line Items]
Royalty rate				8.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Customer relationships
Business Acquisition [Line Items]
Discount rate				13.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Backlog
Business Acquisition [Line Items]
Discount rate				10.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Non-compete
Business Acquisition [Line Items]
Discount rate				13.00%
Ateb
Business Acquisition [Line Items]
Total purchase price, net of cash received		$ 40,700
Cash on hand at signing		902
Intangibles		12,500
Goodwill		$ 20,895
Ateb | Trade names
Business Acquisition [Line Items]
Royalty rate						0.50%
Ateb | Developed technology | Minimum
Business Acquisition [Line Items]
Royalty rate						5.00%
Ateb | Developed technology | Maximum
Business Acquisition [Line Items]
Royalty rate						6.00%
Ateb | Customer relationships
Business Acquisition [Line Items]
Discount rate						15.00%

Business Acquisitions - Total P

Business Acquisitions - Total Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 08, 2016	Jan. 05, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill			$ 332,996		$ 327,724
Total purchase price, net of cash received			$ 4,446	$ 271,458
Aesynt Holding, L.P., Aesynt, Ltd.
Business Acquisition [Line Items]
Cash		$ 8,164
Accounts receivable		43,312
Inventory		19,021
Other current assets		3,787
Total current assets		74,284
Property and equipment		10,389
Intangibles		123,700
Goodwill		163,599
Other non-current assets		968
Total assets		372,940
Current liabilities		26,753
Deferred revenue		25,512
Non-current deferred tax liabilities		38,622
Other non-current liabilities		2,431
Total liabilities		93,318
Total purchase price		279,622
Total purchase price, net of cash received		$ 271,458
Ateb
Business Acquisition [Line Items]
Cash	$ 902
Accounts receivable	7,842
Inventory	225
Other current assets	1,239
Total current assets	10,208
Property and equipment	2,447
Intangibles	12,500
Goodwill	20,895
Other non-current assets	1,009
Total assets	47,059
Current liabilities	2,314
Deferred revenue	2,776
Non-current deferred tax liabilities	0
Other non-current liabilities	367
Total liabilities	5,457
Total purchase price	41,602
Total purchase price, net of cash received	$ 40,700
2016 Acquisitions Aesynt and Ateb
Business Acquisition [Line Items]
Cash					9,066
Accounts receivable					51,154
Inventory					19,246
Other current assets					5,026
Total current assets					84,492
Property and equipment					12,836
Intangibles					136,200
Goodwill					184,494
Other non-current assets					1,977
Total assets					419,999
Current liabilities					29,067
Deferred revenue					28,288
Non-current deferred tax liabilities					38,622
Other non-current liabilities					2,798
Total liabilities					98,775
Total purchase price					321,224
Total purchase price, net of cash received					$ 312,158

Business Acquisitions - Schedul

Business Acquisitions - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 08, 2016	Jan. 05, 2016	Jun. 30, 2017
Aesynt Holding, L.P., Aesynt, Ltd.
Identifiable Intangible Assets
Total purchased intangible assets		$ 123,700
Aesynt Holding, L.P., Aesynt, Ltd. | In-process research and development (IPR&D)
Identifiable Intangible Assets
Fair value of indefinite-lived identifiable intangible assets purchased		3,900
Aesynt Holding, L.P., Aesynt, Ltd. | Customer relationships
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		58,200
Aesynt Holding, L.P., Aesynt, Ltd. | Customer relationships | Minimum
Identifiable Intangible Assets
Weighted average useful life (in years)			14 years
Aesynt Holding, L.P., Aesynt, Ltd. | Customer relationships | Maximum
Identifiable Intangible Assets
Weighted average useful life (in years)			16 years
Aesynt Holding, L.P., Aesynt, Ltd. | Developed technology
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		38,800
Weighted average useful life (in years)			8 years
Aesynt Holding, L.P., Aesynt, Ltd. | Backlog
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		20,200
Aesynt Holding, L.P., Aesynt, Ltd. | Backlog | Minimum
Identifiable Intangible Assets
Weighted average useful life (in years)			1 year
Aesynt Holding, L.P., Aesynt, Ltd. | Backlog | Maximum
Identifiable Intangible Assets
Weighted average useful life (in years)			3 years
Aesynt Holding, L.P., Aesynt, Ltd. | Non-compete
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		1,800
Weighted average useful life (in years)			3 years
Aesynt Holding, L.P., Aesynt, Ltd. | Trade names
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased		$ 800
Weighted average useful life (in years)			1 year
Ateb
Identifiable Intangible Assets
Total purchased intangible assets	$ 12,500
Ateb | Customer relationships
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	8,900
Weighted average useful life (in years)			12 years
Ateb | Developed technology
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	3,400
Weighted average useful life (in years)			5 years
Ateb | Non-compete
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	100
Weighted average useful life (in years)			1 year
Ateb | Trade names
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	$ 100
Weighted average useful life (in years)			1 year

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net income (loss)	$ 837	$ (1,159)	$ (9,917)	$ (1,537)
Weighted-average shares outstanding — basic (in shares)	37,250	35,987	37,046	35,864
Effect of dilutive securities from stock award plans (in shares)	1,120	0	0	0
Weighted-average shares outstanding — diluted (in shares)	38,370	35,987	37,046	35,864
Net income (loss) per share - basic (in dollars per share)	$ 0.02	$ (0.03)	$ (0.27)	$ (0.04)
Net income (loss) per share - diluted (in dollars per share)	$ 0.02	$ (0.03)	$ (0.27)	$ (0.04)
Anti-dilutive weighted-average shares related to stock award plans (in shares)	2,121	1,961	4,039	2,037

Cash and Cash Equivalents and39

Cash and Cash Equivalents and Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 26,936	$ 41,029	$ 54,488	$ 82,217
Payment for contingent consideration	0	$ 3,000
Avantec Heathcare Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment for contingent consideration			$ 3,000
Contingent consideration liability	$ 2,400

Cash and Cash Equivalents and40

Cash and Cash Equivalents and Fair Value of Financial Instruments - Schedule of Financial Assets Measured At Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	$ 1,274	$ 1,245
Total financial assets	1,274	1,245
Total financial liabilities	2,400	2,400
Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	2,400	2,400
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	0	0
Total financial liabilities	0	0
Level 1 | Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	1,274
Total financial assets	1,274	1,245
Total financial liabilities	0	0
Level 2 | Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	0	0
Total financial liabilities	2,400	2,400
Level 3 | Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 2,400	$ 2,400

Cash and Cash Equivalents and41

Cash and Cash Equivalents and Fair Value of Financial Instruments - Interest Rate Swaps (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 26,936,000	$ 54,488,000	$ 41,029,000	$ 82,217,000
Fair value of interest rate swaps	1,274,000	1,245,000
Amounts reclassified into current earnings	$ 0
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount		$ 100,000,000
Derivative, fixed interest rate		0.80%
Fair value of interest rate swaps		$ 1,245,000
Interest Rate Swap | London Interbank Offered Rate (LIBOR)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, basis spread on variable rate		0.00%

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Details (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventories:
Raw materials	$ 16,959	$ 14,322
Work in process	7,834	7,800
Finished goods	56,730	47,175
Total inventories	81,523	69,297
Prepaid expense
Prepaid commissions	10,658	13,176
Other prepaid expenses	15,343	15,470
Total prepaid expense	26,001	28,646
Property and equipment:
Equipment	67,561	64,384
Furniture and fixtures	6,666	6,517
Leasehold improvements	9,436	9,778
Software	36,712	35,607
Construction in progress	9,287	7,211
Property and equipment, gross	129,662	123,497
Accumulated depreciation and amortization	(88,949)	(81,486)
Total property and equipment, net	40,713	42,011
Other long term assets:
Capitalized software, net	35,461	33,233
Other assets	1,493	1,818
Total other long term assets, net	36,954	35,051
Accrued liabilities:
Advance payments from customers	8,588	7,030
Rebates and lease buyouts	5,359	4,025
Group purchasing organization fees	3,068	3,737
Taxes payable	3,818	4,003
Other accrued liabilities	10,061	12,400
Total accrued liabilities	$ 30,894	$ 31,195

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			$ 431,607
Other comprehensive income (loss) before reclassifications	$ 976	$ (4,467)	2,075	$ (4,794)
Amounts reclassified from other comprehensive income (loss), net of tax	(53)	0	(47)	0
Net current-period other comprehensive income (loss), net of tax	923	(4,467)	2,028	(4,794)
Ending balance	449,502		449,502
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(9,841)	(3,057)	(10,764)	(2,730)
Other comprehensive income (loss) before reclassifications	1,076	(4,467)	1,999	(4,794)
Amounts reclassified from other comprehensive income (loss), net of tax	0	0	0	0
Net current-period other comprehensive income (loss), net of tax	1,076	(4,467)	1,999	(4,794)
Ending balance	(8,765)	(7,524)	(8,765)	(7,524)
Unrealized gain (loss) on interest rate swap hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	1,427	0	1,245	0
Other comprehensive income (loss) before reclassifications	(100)	0	76	0
Amounts reclassified from other comprehensive income (loss), net of tax	(53)	0	(47)	0
Net current-period other comprehensive income (loss), net of tax	(153)	0	29	0
Ending balance	1,274	0	1,274	0
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(8,414)	(3,057)	(9,519)	(2,730)
Ending balance	$ (7,491)	$ (7,524)	$ (7,491)	$ (7,524)

Net Investment in Sales-Type 44

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Capital Leased Assets [Line Items]
Net minimum lease payments to be received	$ 27,553	$ 33,591
Less: Unearned interest income portion	(2,206)	(2,763)
Net investment in sales-type leases	25,347	30,828
Less: Short-term portion	(7,923)	(10,243)
Long-term investment in sales-type leases, net	17,424	20,585
Collective allowance for credit losses	$ 200	$ 300
Minimum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length) (in years)	1 year
Maximum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length) (in years)	5 years

Net Investment in Sales-Type 45

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Jun. 30, 2017USD ($)
Leases [Abstract]
Remaining six months of 2017	$ 4,967
2,018	7,911
2,019	5,915
2,020	4,404
2,021	2,647
Thereafter	1,709
Total	$ 27,553

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 327,724
Goodwill acquired	3,176
Foreign currency exchange rate fluctuations	2,096
Ending balance	332,996
Automation and analytics
Goodwill [Roll Forward]
Beginning balance	215,082
Goodwill acquired	3,113
Foreign currency exchange rate fluctuations	1,592
Ending balance	219,787
Medication adherence
Goodwill [Roll Forward]
Beginning balance	112,642
Goodwill acquired	63
Foreign currency exchange rate fluctuations	504
Ending balance	$ 113,209

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (66,730)	$ (54,059)
Foreign currency exchange rate fluctuations	670	(786)
Total intangibles assets, gross carrying amount	246,266	245,128
Total intangible assets, net carrying amount	180,206	190,283
In-process technology
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	0	0
Foreign currency exchange rate fluctuations	0	0
Indefinite-lived intangible assets	3,900	3,900
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	132,744	133,358
Accumulated amortization	(27,182)	(20,930)
Foreign currency exchange rate fluctuations	459	(596)
Net carrying amount	$ 106,021	$ 111,832
Customer relationships | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Customer relationships | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 74,188	$ 73,599
Accumulated amortization	(17,346)	(13,287)
Foreign currency exchange rate fluctuations	158	(159)
Net carrying amount	$ 57,000	$ 60,153
Acquired technology | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	3 years	3 years
Acquired technology | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,689	$ 20,550
Accumulated amortization	(15,689)	(14,083)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 6,000	$ 6,467
Backlog | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Backlog | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	5 years	3 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 8,619	$ 8,667
Accumulated amortization	(4,272)	(3,887)
Foreign currency exchange rate fluctuations	29	(31)
Net carrying amount	$ 4,376	$ 4,749
Trade names | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Trade names | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,226	$ 3,154
Accumulated amortization	(1,283)	(1,264)
Foreign currency exchange rate fluctuations	24	0
Net carrying amount	$ 1,967	$ 1,890
Patents | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	2 years	2 years
Patents | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,900	$ 1,900
Accumulated amortization	(958)	(608)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 942	$ 1,292
Useful life (in years)	3 years	3 years

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 6.8	$ 9.1	$ 13	$ 18.3

Goodwill and Intangible Asset49

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Jun. 30, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining six months of 2017	$ 12,514
2,018	23,293
2,019	17,828
2,020	16,624
2,021	15,053
Thereafter (excluding in-process technology)	90,994
Net carrying amount	$ 176,306

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	Apr. 03, 2017	Dec. 02, 2016	Jan. 05, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Apr. 11, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Repayment of debt and revolving credit facility						$ (70,500,000)	$ (22,500,000)
Interest expense				$ 1,500,000	$ 1,200,000	3,000,000	$ 2,800,000
Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Long-term Line of Credit, Gross				200,000,000		200,000,000		$ 200,000,000		$ 260,500,000
Proceeds from lines of credit						10,000,000
Repayment of debt and revolving credit facility						(70,500,000)		(105,000,000)
Long-term debt				194,436,000		194,436,000		194,436,000		254,141,000
Fair value of debt				200,900,000		200,900,000		200,900,000
Wells Fargo Bank, National Association | Secured Debt | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 400,000,000
Annual capital expenditure limitation per Credit Agreement			35,000,000						$ 45,000,000
Maximum allowed non-permitted investments per Credit Agreement			10,000,000						$ 20,000,000
Deferred issuance cost, gross			$ 7,900,000
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option One | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			1.50%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option One | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			2.25%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.25%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Wells Fargo Bank, National Association | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Line of Credit, Gross				12,500,000		12,500,000		12,500,000		68,000,000
Proceeds from lines of credit						10,000,000
Repayment of debt and revolving credit facility						(65,500,000)
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 200,000,000
Debt instrument, term (in years)			5 years
Proceeds from lines of credit	$ 10,000,000	$ 40,000,000	$ 55,000,000
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit | Minimum
Debt Instrument [Line Items]
Unused capacity, percentage			0.20%
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit | Maximum
Debt Instrument [Line Items]
Unused capacity, percentage			0.35%
Wells Fargo Bank, National Association | Term Loan Facility
Debt Instrument [Line Items]
Long-term Line of Credit, Gross				$ 187,500,000		187,500,000		$ 187,500,000		$ 192,500,000
Proceeds from lines of credit						0
Repayment of debt and revolving credit facility						$ (5,000,000)
Wells Fargo Bank, National Association | Term Loan Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 200,000,000
Debt instrument, term (in years)			5 years
Principal periodic payment, percent, years one and two			5.00%
Principal periodic payment, percent, years three and four			10.00%
Principal periodic payment, percent, year five			15.00%
Proceeds from lines of credit			$ 200,000,000
Wells Fargo Bank, National Association | Letter of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 10,000,000
Wells Fargo Bank, National Association | Letter of Credit | Line of Credit | Minimum
Debt Instrument [Line Items]
Commitment fee percentage			1.50%
Wells Fargo Bank, National Association | Letter of Credit | Line of Credit | Maximum
Debt Instrument [Line Items]
Commitment fee percentage			2.25%
Wells Fargo Bank, National Association | Bridge Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 10,000,000

Debt - Components of Debt (Deta

Debt - Components of Debt (Details) - USD ($) $ in Thousands	6 Months Ended		18 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017
Components of beginning debt balance [Abstract]
Long term debt, current portion, net of deferred issuance cost at beginning of period	$ 8,410
Long term debt, net of deferred issuance cost at beginning of period	245,731
Debt Borrowing, Repayment, Amortization during period [Abstract]
Repayment of debt and revolving credit facility	(70,500)	$ (22,500)
Amortization of deferred issuance cost	795	$ 795
Components of ending debt balance [Abstract]
Long term debt, current portion, net of deferred issuance cost at end of period	10,910		$ 10,910
Long term debt, net of deferred issuance cost at end of period	183,526		183,526
Wells Fargo Bank, National Association
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	260,500
Deferred issuance cost, net at beginning of period	(6,359)
Total Debt, net of deferred issuance cost at beginning of period	254,141
Long term debt, current portion, net of deferred issuance cost at beginning of period	8,410
Long term debt, net of deferred issuance cost at beginning of period	245,731
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	10,000
Deferred issuance cost, gross	0
Increase in borrowings net of deferred issuance cost	10,000
Repayment of debt and revolving credit facility	(70,500)		(105,000)
Amortization of deferred issuance cost	795
Decrease in repayment/amortization net of deferred issuance cost	(69,705)
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	200,000		200,000
Deferred issuance cost, net at end of period	(5,564)		(5,564)
Total Debt, net of deferred issuance cost at end of period	194,436		194,436
Long term debt, current portion, net of deferred issuance cost at end of period	10,910		10,910
Long term debt, net of deferred issuance cost at end of period	183,526		183,526
Wells Fargo Bank, National Association | Term Loan Facility
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	192,500
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	0
Repayment of debt and revolving credit facility	(5,000)
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	187,500		187,500
Wells Fargo Bank, National Association | Revolving Credit Facility
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	68,000
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	10,000
Repayment of debt and revolving credit facility	(65,500)
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	$ 12,500		$ 12,500

Deferred revenue (Details)

Deferred revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Revenue Recognition [Abstract]
Deferred service revenue, cost of sales, current	$ 13,900	$ 14,200
Deferred service revenue, noncurrent portion	$ 16,332	$ 17,051

Commitments and Contingencies53

Commitments and Contingencies (Details) $ in Thousands	Jun. 30, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remaining six months of 2017	$ 6,387
2,018	12,411
2,019	12,250
2,020	10,979
2,021	10,300
Thereafter	31,120
Total minimum future lease payments	83,447
Purchase obligation due within the next twelve months	$ 60,900

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Annual effective tax rate	41.10%	38.30%
Statutory income tax rate	35.00%	35.00%
Unrecognized tax benefits	$ 7		$ 6.5
Accrued interest and penalties	$ 1.1		$ 0.7

Employee Benefits and Share-B55

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 5,545	$ 5,495	$ 11,056	$ 9,386
Cost of product and service revenues
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	845	644	1,827	1,193
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	810	801	1,707	1,442
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 3,890	$ 4,050	$ 7,522	$ 6,751

Employee Benefits and Share-B56

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	4 years 8 months 1 day	4 years 11 months 1 day	4 years 8 months 1 day	4 years 11 months 1 day
Expected volatility, %	28.30%	31.50%	29.70%	32.00%
Risk free interest rate, %	1.78%	1.41%	1.84%	1.40%
Estimated forfeiture rate %	7.70%	8.60%	7.70%	8.60%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, %, Min	25.80%	25.80%	25.80%	25.80%
Expected volatility, %, Max	32.80%	34.80%	32.80%	34.80%
Risk free interest rate, %, Min	0.52%	0.26%	0.52%	0.26%
Risk free interest rate, %, Max	1.31%	0.79%	1.31%	0.79%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 months	6 months	6 months	6 months
Employee Stock Purchase Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	2 years	2 years	2 years	2 years

Employee Benefits and Share-B57

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Number of Shares
Outstanding at beginning of period (in shares)			3,214
Granted (in shares)			409
Exercised (in shares)			(423)
Expired (in shares)			(3)
Forfeited (in shares)			(56)
Outstanding at end of period (in shares)	3,141		3,141		3,214
Exercisable at end of period (in shares)	1,382		1,382
Vested and expected to vest at end of period (in shares)	2,985		2,985
Weighted Average Exercise Price
Outstanding beginning balance (in dollars per share)			$ 26.06
Granted (in dollars per share)			37.21
Exercised (in dollars per share)			21.69
Expired (in dollars per share)			24.36
Forfeited (in dollars per share)			32.14
Outstanding ending balance (in dollars per share)	$ 27.99		27.99		$ 26.06
Exercisable at end of period (in dollars per share)	21.61		21.61
Vested and expected to vest at end of period (in dollars per share)	$ 27.66		$ 27.66
Weighted-average remaining years, outstanding			7 years 5 months 5 days		7 years 3 months 18 days
Weighted-average remaining years, exercisable at end of period			5 years 7 months 2 days
Weighted-average remaining years, vested and expected to vest at at end of period			7 years 4 months 2 days
Aggregate Intrinsic Value
Aggregate intrinsic value, outstanding at end of period	$ 47,445		$ 47,445		$ 26,331
Aggregate intrinsic value, exercisable at end of period	29,696		29,696
Aggregate intrinsic value, vested and expected to vest at end of period	$ 46,078		$ 46,078
Employee Stock Option
Aggregate Intrinsic Value
Weighted-average fair value (in dollars per share)	$ 11.31	$ 9.03	$ 10.92	$ 8.59
Intrinsic value of options exercised	$ 4,900	$ 2,200	$ 7,800	$ 2,900
Unrecognized compensation cost of unvested stock options	$ 14,300		$ 14,300
Weighted average period of compensation cost not yet recognized (in years)			2 years 10 months 24 days

Employee Benefits and Share-B58

Employee Benefits and Share-Based Compensation - Restricted Stock Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Restricted Stock Units (RSUs)
Number of Shares
Outstanding at beginning of period (in shares)	505
Granted (in shares)	86
Vested (in shares)	(96)
Forfeited (in shares)	(11)
Outstanding and unvested at end of period (in shares)	484		505
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 31.42
Granted (in dollars per share)	37.21	$ 28.09
Vested (in dollars per share)	28.88
Forfeited (in dollars per share)	32.17
Outstanding and unvested (in dollars per share)	$ 32.93		$ 31.42
Weighted-average remaining years, outstanding and unvested	1 year 4 months 24 days		1 year 7 months
Aggregate Intrinsic Value
Outstanding and unvested at end of period	$ 20,901		$ 17,135
Unrecognized compensation cost	$ 12,800
Weighted average period of compensation cost not yet recognized (in years)	2 years 6 months 29 days
Restricted Stock Awards
Number of Shares
Outstanding at beginning of period (in shares)	30
Granted (in shares)	24
Vested (in shares)	(30)
Forfeited (in shares)	0
Outstanding and unvested at end of period (in shares)	24		30
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 31.57
Granted (in dollars per share)	41.10
Vested (in dollars per share)	31.58
Forfeited (in dollars per share)	0
Outstanding and unvested (in dollars per share)	$ 41.03		$ 31.57
Aggregate Intrinsic Value
Unrecognized compensation cost	$ 800
Weighted average period of compensation cost not yet recognized (in years)	10 months 21 days

Employee Benefits and Share-B59

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Unit Activity (Details) - 2009 Plan - Performance Shares - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Number of Shares
Outstanding at beginning of period (in shares)	184
Granted (in shares)	126
Vested (in shares)	(69)
Canceled (in shares)	0
Outstanding and unvested at end of period (in shares)	241
Weighted-Average Grant Date Fair Value Per Share
Outstanding and unvested (in dollars per share)	$ 24.89
Granted (in dollars per share)	32.37	$ 24.66
Vested (in dollars per share)	24.43
Canceled (in dollars per share)	0
Outstanding and unvested (in dollars per share)	$ 28.94
Unrecognized compensation cost	$ 3.5
Weighted average period of compensation cost not yet recognized (in years)	1 year 6 months 15 days

Employee Benefits and Share-B60

Employee Benefits and Share-Based Compensation - Employee Stock Purchase Plan (ESPP) Activity (Details) - Nineteen Ninety Seven Employee Stock Purchase Plan - Employee Stock Purchase Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1.9
Weighted average period of compensation cost not yet recognized (in years)	1 year 4 months 6 days
Purchases under ESPP (in shares)	259	198
Exercised (in dollars per share)	$ 25.51	$ 22.74

Employee Benefits and Share-B61

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Jun. 30, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	8,772
Nineteen Ninety Seven Employee Stock Purchase Plan | ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	2,572
2009 Plan | Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	3,141
2009 Plan | Non-vested restricted share awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	749
2009 Plan | Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	2,310

Employee Benefits and Share-B62

Employee Benefits and Share-Based Compensation - Stock Repurchase Program (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Aug. 02, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares acquired (in shares)	0	0
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase, authorized amount			$ 50,000,000
2016 and 2014 Share Repurchase Programs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase, remaining authorized repurchase amount	$ 54,900,000

Segment and Geographical Info63

Segment and Geographical Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)segment	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Segment Reporting [Abstract]
Number of segments | segment			2
Segment Reporting Information [Line Items]
Revenues	$ 180,885	$ 172,907	$ 331,439	$ 343,911
Cost of revenues	102,910	94,890	189,272	185,949
Gross profit	77,975	78,017	142,167	157,962
Operating expenses	80,379	78,135	161,807	156,228
Income (loss) from operations	(2,404)	(118)	(19,640)	1,734
Property and equipment, net	40,713		40,713		$ 42,011
United States
Segment Reporting Information [Line Items]
Revenues	153,285	145,988	285,565	289,481
Property and equipment, net	35,041		35,041		36,497
Rest of world
Segment Reporting Information [Line Items]
Revenues	27,600	26,919	45,874	54,430
Property and equipment, net	5,672		5,672		$ 5,514
Operating segments
Segment Reporting Information [Line Items]
Revenues	180,885	172,907	331,439	343,911
Cost of revenues	102,910	94,890	189,272	185,949
Gross profit	77,975	78,017	142,167	157,962
Operating expenses	59,153	55,551	121,096	113,367
Income (loss) from operations	18,822	22,466	21,071	44,595
Operating segments | Automation and analytics
Segment Reporting Information [Line Items]
Revenues	148,427	148,660	272,598	297,605
Cost of revenues	80,716	78,366	149,477	155,573
Gross profit	67,711	70,294	123,121	142,032
Operating expenses	49,054	49,780	99,801	101,985
Income (loss) from operations	18,657	20,514	23,320	40,047
Operating segments | Medication adherence
Segment Reporting Information [Line Items]
Revenues	32,458	24,247	58,841	46,306
Cost of revenues	22,194	16,524	39,795	30,376
Gross profit	10,264	7,723	19,046	15,930
Operating expenses	10,099	5,771	21,295	11,382
Income (loss) from operations	165	1,952	(2,249)	4,548
Corporate
Segment Reporting Information [Line Items]
Operating expenses	$ 21,226	$ 22,584	$ 40,711	$ 42,861

Restructuring Expenses (Details

Restructuring Expenses (Details) $ in Thousands	Feb. 15, 2017USD ($)Employee	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)Employee	Jun. 30, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated | Employee	100		36
Restructuring expected cost	$ 4,900
Restructuring expenses		$ 603		$ 4,368
Cost of revenue
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		1,697
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		587		1,655
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		16		1,016
Operating segments | Automation and analytics
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		485		3,237
Operating segments | Automation and analytics | Cost of revenue
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		1,266
Operating segments | Automation and analytics | Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		485		1,491
Operating segments | Automation and analytics | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		480
Operating segments | Medication adherence
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		596
Operating segments | Medication adherence | Cost of revenue
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		431
Operating segments | Medication adherence | Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		62
Operating segments | Medication adherence | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		103
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		118		535
Corporate | Cost of revenue
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		0		0
Corporate | Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		102		102
Corporate | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		16		433
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring expected cost	3,800
Restructuring expenses			$ 1,700	3,800
Payments for restructuring				3,100
Facility-related cost
Restructuring Cost and Reserve [Line Items]
Restructuring expected cost	$ 1,100
Payments for restructuring				100
Restructuring costs incurred				600
Accrued severance and related expenses | Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, unpaid balance in accrued compensation		700		700
Accrued severance and related expenses | Facility-related cost
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, unpaid balance in accrued compensation		$ 500		$ 500

Subsequent Event (Details)

Subsequent Event (Details) - Wells Fargo Bank, National Association - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 07, 2017	Apr. 03, 2017	Dec. 02, 2016	Jan. 05, 2016	Jun. 30, 2017
Subsequent Event [Line Items]
Proceeds from lines of credit						$ 10,000
Revolving Credit Facility
Subsequent Event [Line Items]
Proceeds from lines of credit						$ 10,000
Line of Credit | Revolving Credit Facility
Subsequent Event [Line Items]
Proceeds from lines of credit			$ 10,000	$ 40,000	$ 55,000
Line of Credit | Revolving Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Proceeds from lines of credit	$ 12,000	$ 15,000